Study on the Progress of Breast Cancer Cases in Males and the Assessment of Relapse Risk
NCT03800355 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 777
Last updated 2025-02-26
Summary
An observational, Other Designs (OD) post-marketing, multicenter study, which will obtain retrospective data from male patients diagnosed with invasive breast cancer between 2000 and 2019 in the medical oncology departments of hospitals that are associated with Spanish Breast Cancer Research Group (GEICAM) (using information obtained from patient medical histories).
Conditions
- Breast Cancer, Male
Sponsors & Collaborators
-
Fundación ADEY
collaborator UNKNOWN -
Spanish Breast Cancer Research Group
lead OTHER
Principal Investigators
-
Chief Medical Investigator · Hospital Universitario Ramón y Cajal, Madrid, Spain
-
Chief Medical Investigator · Fundación Onkologikoa, San Sebastián, Spain
Eligibility
- Min Age
- 18 Years
- Sex
- MALE
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2018-09-14
- Primary Completion
- 2023-03-31
- Completion
- 2025-02-24
Countries
- Spain
Study Locations
More Related Trials
-
Safety and Efficacy of Hormone Therapy With Letrozole in Postmenopausal Women With Breast Cancer
NCT00330317 ·Status: COMPLETED ·Phase: PHASE3
-
Adherence to Oral Therapies in Advanced Breast and Prostate Cancers
NCT06435546 ·Status: COMPLETED ·Phase: NA
-
Oocyte Recovery During Tamoxifen Adjuvant Therapy
NCT02355600 ·Status: UNKNOWN
-
Impact of Obesity on the Efficacy of Endocrine Therapy With Aromatase Inhibitors
NCT01758146 ·Status: UNKNOWN ·Phase: PHASE3
-
Study Evaluating CCI-779 and Letrozole in Post-menopausal Women With Breast Cancer
NCT00083993 ·Status: TERMINATED ·Phase: PHASE3
-
Prospective Observational Study of Antitumor Activity Correlation Between Hormonal Therapy and Expression miRNA100
NCT02950207 ·Status: UNKNOWN
-
Investigating Patient Satisfaction With Oral Anti-cancer Treatment in Patients With Hormone-receptor Positive, HER2-receptor Negative, Advanced Breast Cancer
NCT02875951 ·Status: UNKNOWN
-
Efficacy of Tamoxifen Versus Toremifene in CYP2D6 IM/PM of Premenopausal Patients With ER-positive Early Breast Cancer
NCT03351062 ·Status: RECRUITING ·Phase: PHASE3
-
10 Year Coronary Heart Disease (CHD) Risk Evaluation and Its Treatment Pattern Analysis in Postmenopausal Early Breast Cancer (EBC) Patients Taking Aromatase Inhibitors (AI)
NCT00885612 ·Status: COMPLETED
-
TOxicity After Radiotherapy in breAst CancEr Survivors (ThORACeS) - A Retrospective Cohort Study
NCT02471079 ·Status: COMPLETED
-
S0511, Goserelin and Anastrozole in Treating Men With Recurrent or Metastatic Breast Cancer
NCT00217659 ·Status: WITHDRAWN ·Phase: PHASE2
-
OPTimizing Irradiation Through Molecular Assessment of Lymph Node (OPTIMAL)
NCT02335957 ·Status: COMPLETED ·Phase: NA
-
CYP2D6 Genotyping by AmpliChipTM CYP450 for Tamoxifen-Treated Breast Cancer Patients
NCT00815555 ·Status: UNKNOWN
-
Preoperative Window Opportunity Study With Giredestrant or Tamoxifen in Premenopausal Women With ER+/HER2[-] & Ki67≥10%
NCT05659563 ·Status: COMPLETED ·Phase: PHASE2
-
This is a Multicenter, Randomized, Double-blind, Placebo-controlled Phase III Clinical Study Evaluating the Efficacy and Safety of FCN-437c Versus Placebo in Combination With Letrozole or Anastrozole ± Goserelin in Women With HR+ and HER2- Advanced Breast Cancer.
NCT05439499 ·Status: UNKNOWN ·Phase: PHASE3
-
Evaluation of the Use of AZD6244 to Induce Increased ER Expression and Anti-Estrogen Response in ER-Negative/Low Breast Cancer
NCT01313039 ·Status: COMPLETED ·Phase: EARLY_PHASE1
-
Elacestrant for Treating ER+/HER2- Breast Cancer Patients With ctDNA Relapse (TREAT ctDNA)
NCT05512364 ·Status: RECRUITING ·Phase: PHASE3
-
Follow-up of Sequential Chemotherapy and Stimulation for Fertility Preservation in Young Patients With Breast Cancer
NCT03795246 ·Status: ACTIVE_NOT_RECRUITING ·Phase: NA
-
Promoting Men's Adherence to BRCA1/2 Germline Genetic Testing
NCT04683068 ·Status: COMPLETED ·Phase: NA
-
Feasibility Study for the Determination of Oxysterols in Patients With Breast Cancer Receiving Hormonal Therapy With Tamoxifen or Not
NCT01553903 ·Status: COMPLETED ·Phase: PHASE4
-
ETHAN - ET for Male BC
NCT05501704 ·Status: RECRUITING ·Phase: PHASE2
-
Biological Response to Tamoxifen (TAM) in Patients With Breast Cancer Non Metastatic RH+
NCT01220076 ·Status: COMPLETED ·Phase: PHASE2
-
Establishment of Molecular Profiling for Individual Clinical Routine Treatment Decision in Early Breast Cancer
NCT03904173 ·Status: ACTIVE_NOT_RECRUITING
-
Extended Adjuvant Treatment With Letrozole in Breast Cancer Who Complete 5 Years of Toremifene
NCT01072318 ·Status: UNKNOWN ·Phase: PHASE4
-
Study to Assess the Efficacy and Safety of the Epigenetic Modifying Effects of CC-486 (Oral Azacitidine) in Combination With Fulvestrant
NCT02374099 ·Status: TERMINATED ·Phase: PHASE2